The process of evaluating the effectiveness of intravenous immunoglobulin (IVIG) therapy involves observing and documenting changes in the patient’s condition following treatment. Success is indicated by improvements in the specific symptoms or markers associated with the underlying condition for which IVIG was prescribed. For example, if IVIG is used to treat an autoimmune disorder affecting the muscles, a sign of efficacy would be increased muscle strength and reduced fatigue.
Assessing therapeutic success is vital for optimizing patient care. It allows for timely adjustments to treatment plans, including dosage modifications or exploration of alternative therapies, if the initial approach proves inadequate. Historically, this assessment relied heavily on subjective observations; however, advancements in diagnostic testing now enable a more objective evaluation of treatment response through quantifiable measures.